Bausch + Lomb (NYSE:BLCO) Given New $15.50 Price Target at Evercore ISI

Bausch + Lomb (NYSE:BLCO) had its target price boosted by Evercore ISI from $15.00 to $15.50 in a report published on Tuesday morning, Benzinga reports. They currently have an in-line rating on the stock.

BLCO has been the topic of several other research reports. Evercore cut their target price on Bausch + Lomb from $17.00 to $15.00 and set an in-line rating on the stock in a research report on Thursday, May 2nd. Morgan Stanley upgraded Bausch + Lomb from an equal weight rating to an overweight rating and upped their target price for the company from $16.00 to $18.00 in a research report on Monday, May 6th. Needham & Company LLC restated a hold rating on shares of Bausch + Lomb in a research report on Wednesday, May 1st. Royal Bank of Canada cut their target price on Bausch + Lomb from $20.00 to $18.00 and set an outperform rating on the stock in a research report on Monday, April 22nd. Finally, HC Wainwright reiterated a buy rating and issued a $20.00 price target on shares of Bausch + Lomb in a report on Thursday, May 2nd. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $19.32.

Bausch + Lomb Trading Up 0.5 %

NYSE BLCO opened at $14.67 on Tuesday. The business’s 50-day moving average price is $14.88 and its two-hundred day moving average price is $15.32. Bausch + Lomb has a 12 month low of $13.16 and a 12 month high of $21.23. The firm has a market capitalization of $5.16 billion, a PE ratio of -15.28, a price-to-earnings-growth ratio of 1.47 and a beta of 0.48. The company has a current ratio of 1.70, a quick ratio of 1.03 and a debt-to-equity ratio of 0.68.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). Bausch + Lomb had a negative net margin of 7.81% and a positive return on equity of 3.60%. The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, analysts expect that Bausch + Lomb will post 0.64 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Rokos Capital Management LLP bought a new position in shares of Bausch + Lomb in the first quarter valued at approximately $5,602,000. Invenomic Capital Management LP bought a new position in shares of Bausch + Lomb in the first quarter valued at approximately $6,817,000. Whitebox Advisors LLC increased its position in shares of Bausch + Lomb by 29.3% during the first quarter. Whitebox Advisors LLC now owns 1,206,303 shares of the company’s stock valued at $20,869,000 after acquiring an additional 273,484 shares during the last quarter. Gabelli Funds LLC increased its position in shares of Bausch + Lomb by 3.3% during the first quarter. Gabelli Funds LLC now owns 312,000 shares of the company’s stock valued at $5,398,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Fore Capital LLC purchased a new stake in shares of Bausch + Lomb during the first quarter valued at approximately $384,000. Institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.